MediWound (MDWD) to Release Earnings on Wednesday

MediWound (NASDAQ:MDWD - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $5.20 million for the quarter.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period last year, the business posted ($0.19) earnings per share. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Price Performance

MediWound stock opened at $19.92 on Wednesday. MediWound has a one year low of $12.78 and a one year high of $24.00. The business has a fifty day moving average price of $17.10 and a 200-day moving average price of $17.50. The firm has a market capitalization of $215.30 million, a P/E ratio of -6.87 and a beta of 0.30.

Analyst Upgrades and Downgrades

MDWD has been the subject of several research analyst reports. Craig Hallum started coverage on MediWound in a research note on Friday, February 28th. They set a "buy" rating and a $39.00 price target for the company. StockNews.com upgraded MediWound to a "sell" rating in a report on Friday, March 21st. Alliance Global Partners began coverage on MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of MediWound in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, MediWound presently has a consensus rating of "Moderate Buy" and an average price target of $29.75.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.